International Journal of Pharma and Bio Sciences
    ISSN 0975-6299

Int J Pharm Bio Sci Volume 13 Issue 1, January - March, Pages:116-124

Significance of Triglyceride Glucose Index and Various Atherogenic Indices in Uncontrolled Type II Diabetes Mellitus Patients

Lohitha Polisetty, Aleti Lakshmi Manohari and Harini Mullapudy

Diabetes mellitus is a well-established risk factor for cardiovascular disease (CVD), which is more pronounced when uncontrolled. The characteristic dyslipidemic pattern adds to the cause of cardiovascular disease in Type 2 diabetes mellitus patients. Various Atherogenic indices like Atherogenic index of plasma (AIP), Castelli risk index (CRI-I), Castelli risk index (CRI -II), and Atherogenic coefficient (AC) have been found to predict cardiovascular risk even in the absence of significant changes in the individual lipid profile parameters. Our study aimed to assess the significance between Triglyceride Glucose Index (TyG index) and various Atherogenic indices like  Atherogenic index of plasma (AIP), Castelli risk index (CRI-I), Castelli risk index (CRI -II), and Atherogenic coefficient (AC). The objective of our study is to establish a correlation between Triglyceride Glucose Index (TyG index) and various Atherogenic indices with an intent to use it as a cheap marker for predicting atherosclerotic risk in establishing CVD in uncontrolled Type 2 diabetes mellitus patients.. A case-control study was conducted with 100 uncontrolled Type 2 DM patients and 100 controlled Type 2 DM patients. FBS, HbA1C, Lipid profile - Total Cholesterol (TC), Triacylglycerol (TG), HDLc were measured on a fully automated analyzer with commercially available kits. LDLc, Atherogenic indices (AIP, AC, CRI-I, CRI-II), and Triglyceride Glucose Index (TyG) were calculated using standardized formulas.There was a significant association between the Triglyceride Glucose Index (TyG) and various Atherogenic indices between the cases and control groups, so Triglyceride Glucose Index (TyG) can be suggested to use as a cheap marker in predicting the risk of atherosclerotic CVD in uncontrolled Type-2 Diabetic Mellitus patients.

Keywords: Diabetes mellitus (DM), Cardiovascular disease (CVD), Triglyceride Glucose Index (TyG), Atherogenic index of plasma (AIP), Castelli Risk Index (CRI-I), Castelli Risk Index (CRI -II), Atherogenic coefficient (AC)
Full HTML:


  1. King H, Rewers M. Global estimates for the prevalence of diabetes mellitus and impaired glucose tolerance in adults: WHO Ad Hoc Diabetes Reporting Group. Diabetes Care. 1993;16(1):157-77. doi: 10.2337/diacare.16.1.157, PMID 8123057.
  2. International Diabetes Federation. Diabetes atlas 2000. Brussels: International Diabetes Federation; 2000.
  3. Berger B, Stenström G, Sundkvist G. Incidence, prevalence, and mortality of diabetes in a large population: a report from the Skaraborg Diabetes Registry. Diabetes Care. 1999;22(5):773-8. doi: 10.2337/diacare.22.5.773, PMID 10332680.
  4. Vergès BL. Dyslipidaemia in diabetes mellitus, Review of the main lipoprotein abnormalities and their consequences in the development of atherogenesis. Diabetes Metab. 1999;25(3);Suppl 3:32-40. PMID 10421991.
  5. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 1997;20(7):1183-97. doi: 10.2337/diacare.20.7.1183, PMID 9203460, Google Scholar.
  6. Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R, Kitzmiller J, Knowler WC, Lebovitz H, Lernmark A, Nathan D, Palmer J, Rizza R, Saudek C, Shaw J, Steffes M, Stern M, Tuomilehto J, Zimmet P, Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care. 2003;26(11):3160-7. doi: 10.2337/diacare.26.11.3160, PMID 14578255, Google Scholar.
  7. Gu K, Cowie CC, Harris MI. Diabetes and decline in heart disease mortality in US adults. JAMA. 1999;281(14):1291-7. doi: 10.1001/jama.281.14.1291, PMID 10208144, Google Scholar.
  8. Prevalence of small vessel and large vessel disease in diabetic patients from 14 centres. The World Health Organisation Multinational Study of vascular Disease in Diabetics. Diabetologia. 1985;28(S1);Suppl:615-40. doi: 10.1007/BF00290267, PMID PubMed, Google Scholar.
  9. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in non-diabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339(4):229-34. doi: 10.1056/NEJM199807233390404, PMID 9673301, Google Scholar.
  10. Evans JM, Wang J, Morris AD. Comparison of cardiovascular risk between patients with type 2 diabetes and those who had had a myocardial infarction: cross sectional and cohort studies. BMJ. 2002;324(7343):939-42. (PMC Free article). doi: 10.1136/bmj.324.7343.939, PMID 11964337, Google Scholar.
  11. Echouffo-Tcheugui JB, Kengne AP. On the importance of global cardiovascular risk assessment in people with type 2 diabetes. Prim Care Diabetes. 2013;7(2):95-102. doi: 10.1016/j.pcd.2013.03.002, PMID 23623209, Google Scholar.
  12. Grundy SM, Cleeman JI, Merz CN, Brewer HB, Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC, Jr, Stone NJ, Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. J Am Coll Cardiol. 2004;44(3):720-32. doi: 10.1016/j.jacc.2004.07.001, PMID [CrossRef], Google Scholar.
  13. Gotto AM, Jr, Brinton EA. Assessing low levels of high-density lipoprotein cholesterol as a risk factor in coronary heart disease a working group report and update. J Am Coll Cardiol. 2004;43(5):717-24. doi: 10.1016/j.jacc.2003.08.061, PMID [CrossRef], Google Scholar.
  14. Nwagha UI, Ikekpeazu EJ, Ejezie FE, Neboh EE, Maduka IC. Atherogenic index of plasma as useful predictor of cardiovascular risk among postmenopausal women in Enugu, Nigeria. Afr Health Sci. 2010;10(3):248-52. PMID 21327136.
  15. Zhang M, Wang B, Liu Y, Sun X, Luo X, Wang C, Li L, Zhang L, Ren Y, Zhao Y, Zhou J, Han C, Zhao J, Hu D. Cumulative increased risk of incident type 2 diabetes mellitus with increasing triglyceride glucose index in normal-weight people: the Rural Chinese Cohort Study. Cardiovasc Diabetol. 2017;16(1):30. doi: 10.1186/s12933-017-0514-x, PMID 28249577.
  16. Lee DY, Lee ES, Kim JH, Park SE, Park CY, Oh KW, Park SW, Rhee EJ, Lee WY. Predictive value of triglyceride glucose index for the risk of incident diabetes: a 4-year retrospective longitudinal study. PLOS ONE. 2016;11(9):e0163465. doi: 10.1371/journal.pone.0163465, PMID 27682598.
  17. Jian S, Su-Mei N, Xue C, Jie Z, Xue-sen W. Association and interaction between triglyceride–glucose index and obesity on risk of hypertension in middle-aged and elderly adults. Clin Exp Hypertens. 2017;39(8):732-9. doi: 10.1080/10641963.2017.1324477, PMID 28737433.
  18. Khan SH, Sobia F, Niazi NK, Manzoor SM, Fazal N, Ahmad F. Metabolic clustering of risk factors: evaluation of triglyceride-glucose index (TyG index) for evaluation of insulin resistance. Diabetol Metab Syndr. 2018;10:74. doi: 10.1186/s13098-018-0376-8, PMID 30323862.
  19. Fox CS, Golden SH, Anderson C, Bray GA, Burke LE, de Boer IH, Deedwania P, Eckel RH, Ershow AG, Fradkin J, Inzucchi SE, Kosiborod M, Nelson RG, Patel MJ, Pignone M, Quinn L, Schauer PR, Selvin E, Vafiadis DK; American Heart Association Diabetes Committee of the Council on Lifestyle and Cardiometabolic Health, Council on Clinical Cardiology, Council on Cardiovascular and Stroke Nursing, Council on Cardiovascular Surgery and Anesthesia, Council on Quality of Care and Outcomes Research, and the American Diabetes Association. Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association. Circulation. 2015 Aug 25;132(8):691-718. doi: 10.1161/CIR.0000000000000230.PMID:26246173.20.
  20. Goto A, Arah OA, Goto M, Terauchi Y, Noda M. Severe hypoglycaemia and cardiovascular disease: systematic review and meta-analysis with bias analysis. Bmj. Jul 29 2013;347:f4533. 
  21. Newman JD, Schwartzbard AZ, Weintraub HS, Goldberg IJ, Berger JS. Primary Prevention of Cardiovascular Disease in Diabetes Mellitus. J Am Coll Cardiol. 2017 Aug 15;70(7):883-893. doi: 10.1016/j.jacc.2017.07.001. PMID: 28797359; PMCID: PMC5656394.
  22. Look AHEAD Research Group, Wing, R. R., Bolin, P., Brancati, F. L., Bray, G. A., Clark, J. M., Coday, M., Crow, R. S., Curtis, J. M., Egan, C. M., Espeland, M. A., Evans, M., Foreyt, J. P., Ghazarian, S., Gregg, E. W., Harrison, B., Hazuda, H. P., Hill, J. O., Horton, E. S., Hubbard, V. S., … Yanovski, S. Z. (2013). Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. The New England journal of medicine369(2), 145–154. PMID: 23796131
  23. Einarson TR, Acs A, Ludwig C, Panton UH. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007-2017. Cardiovasc Diabetol. 2018;17(1):83. doi: 10.1186/s12933-018-0728-6, PMID 29884191.
  24. Martín-Timón I, Sevillano-Collantes C, Segura-Galindo A, Del Cañizo-Gómez FJ. Type 2 diabetes and cardiovascular disease: have all risk factors the same strength? World J Diabetes. 2014;5(4):444-70. doi: 10.4239/wjd.v5.i4.444, PMID 25126392.
  25. Saito I, Folsom AR, Brancati FL, Duncan BB, Chambless LE, McGovern PG. Nontraditional risk factors for coronary heart disease incidence among persons with diabetes: the Atherosclerosis Risk in Communities (ARIC) Study. Ann Intern Med. 2000 Jul 18;133(2):81-91. doi: 10.7326/0003-4819-133-2-200007180-00007. PMID: 10896647.
  26. Fonseca VA. Risk factors for coronary heart disease in diabetes. Ann Intern Med. 2000 Jul 18;133(2):154-6. doi: 10.7326/0003-4819-133-2-200007180-00015. PMID: 10896642.
  27. Nimmanapalli HD, Kasi AD, Devapatla PK, Nuttakki V. Lipid ratios, atherogenic coefficient and atherogenic index of plasma as parameters in assessing cardiovascular risk in type 2 diabetes mellitus. Int J Res Med Sci. 2016;4:2863-9. doi: 10.18203/2320-6012.ijrms20161966.
  28. Khazaal MS. Atherogenic Index of Plasma (AIP) as a parameter in predicting cardiovascular risk in males compared to the conventional dyslipidemic indices (cholesterol ratios). Karbala. J Med. 2013;6(1):1506-13.
  29. Dobiásová M, Frohlich J. The plasma parameter log (TG/HDL C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB lipoprotein depleted plasma. Clin Biochem. 2001;34(7):583-8. doi: 10.1016/s0009-9120(01)00263-6, PMID 11738396.
  30. Bhardwaj S, Bhattacharjee J, Bhatnagar MK, Tyagi S, et al. Atherogenic index of plasma, castelli risk index and atherogenic coefficient- new parameters in assessing cardiovascular risk. Int J Pharm Biol Sci. 2013;3:359-64.
  31. Subia J, Afshan S. Comparison of CVD risk associated with the long term use of contraceptives in young females. J Appl Pharm Sci. 2012;2(11):062-6.
  32. Ridker PM, Rifai N, Cook NR, Bradwin G, Buring JE. Non-HDL cholesterol, apolipoprotein A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA. 2005;294(3):326-33. 12.
  33. Kinosian B, Glick H, Garland G. Cholesterol and coronary heart disease: predicting risks by levels and ratios. Ann Intern Med. 1994;121(9): 641-7. 
  34. Sangmo H, Kyungdo H, Cheol-Young P. The triglyceride glucose index is a simple and low-cost marker associated with atherosclerotic cardiovascular disease: a population-based study. BMC Med. 2020;18(361):1-8
[Download PDF]
Welcome to IJPBS,Pharmaceutics, Novel, drug, delivery, system, Nanotechnology, Pharmacology, Pharmacognosy
Pharmaceutical Fields
Welcome to IJPBS,Pharmaceutics, Novel, drug, delivery, system, Nanotechnology, Pharmacology, Pharmacognosy Pharmaceutics
Welcome to IJPBS,Pharmaceutics, Novel, drug, delivery, system, Nanotechnology, Pharmacology, Pharmacognosy Novel drug delivery system
Welcome to IJPBS,Pharmaceutics, Novel, drug, delivery, system, Nanotechnology, Pharmacology, Pharmacognosy Nanotechnology
Welcome to IJPBS,Pharmaceutics, Novel, drug, delivery, system, Nanotechnology, Pharmacology, Pharmacognosy Pharmacology
Welcome to IJPBS,Pharmaceutics, Novel, drug, delivery, system, Nanotechnology, Pharmacology, Pharmacognosy Pharmacognosy
© Copyright 2009-2015 IJPBS, India. All rights reserved. Specialized online journals by ubijournal. Website by Ubitech Solutions
         Home I Contact I Terms & Conditions